<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess efficacy and tolerability of insulin detemir or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin added to oral therapy for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a treat-to-target titration protocol </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Individuals (n = 476) with HbA(1c) (A1C) 7.5-10.0% were randomized to addition of twice-daily insulin detemir or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin in a parallel-group, multicenter trial </plain></SENT>
<SENT sid="2" pm="."><plain>Over 24 weeks, insulin doses were titrated toward prebreakfast and predinner plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> targets of &lt; or =6.0 mmol/l (&lt; or =108 mg/dl) </plain></SENT>
<SENT sid="3" pm="."><plain>Outcomes assessed included A1C, percentage achieving A1C &lt; or =7.0%, risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, and body weight </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>, respectively (NS) </plain></SENT>
<SENT sid="5" pm="."><plain>In both groups, 70% of participants achieved an A1C &lt;/= 7.0%; [corrected] there was a trend towards [corrected] the proportion achieving this without <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> being [corrected] higher with insulin detemir than with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin (34% [corrected] vs. 25[corrected]%, P = 0.052[corrected]) </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin, the risk for <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> with insulin detemir was reduced by 47% (P &lt; 0.001) and nocturnal <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> by 55% (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Mean <z:mp ids='MP_0005456'>weight gain</z:mp> was 1.2 kg with insulin detemir and 2.8 kg with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin (P &lt; 0.001), and the difference in baseline-adjusted final weight was -1.58 (P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Addition of basal insulin to oral drug therapy in people with suboptimal control of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> achieves guideline-recommended A1C values in most people with aggressive titration </plain></SENT>
<SENT sid="9" pm="."><plain>Insulin detemir compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin achieves this with reduced <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and less <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
</text></document>